Published in Br J Cancer on May 01, 1984
Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2003) 0.96
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Lymphosarcoma: a review of 1269 cases. Medicine (Baltimore) (1961) 5.64
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Computed tomographic scanning of the thorax in the staging of bronchogenic carcinoma. N Engl J Med (1979) 1.27
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J (1978) 1.25
Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. AJR Am J Roentgenol (1978) 1.21
Comparison of plain radiography, conventional tomography, and computed tomography in detecting intrathoracic lymph node metastases from lung carcinoma. Radiology (1982) 1.16
The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer (1978) 1.05
Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer (1980) 1.04
Computed tomography in the evaluation of mediastinal widening. Radiology (1981) 1.02
The role of computed tomography in the initial staging and subsequent management of the lymphomas. J Comput Assist Tomogr (1980) 0.96
Computed tomography of the anterior mediastinum in myasthenia gravis. A radiologic-pathologic correlative study. Radiology (1982) 0.92
Sequential staging in non-Hodgkin's lymphoma. Cancer Treat Rep (1977) 0.86
Posttreatment laparotomy as a guide to management in patients with Hodgkin's disease. Cancer Treat Rep (1982) 0.83
Editorial: Diagnostic radiology--planning for the future. Radiology (1976) 0.79
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol (1992) 3.25
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
Another look at osteoarthritis. Ann Rheum Dis (1979) 3.06
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet (1983) 2.26
Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. Lancet (1974) 2.15
The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol (1988) 2.05
Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes. J Clin Oncol (1990) 2.02
Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG). Br J Cancer (1984) 1.97
An orbital period of 0.94 days for the hot-Jupiter planet WASP-18b. Nature (2009) 1.79
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol (2001) 1.79
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72
The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol (2000) 1.68
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
Iron metabolism in patients undergoing regular dialysis therapy. Br Med J (1971) 1.67
Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (1983) 1.66
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol (2003) 1.59
Central nervous system toxicity of interferon. Br J Cancer (1983) 1.58
The clinical staging of rectal cancer. Br J Surg (1982) 1.55
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol (1991) 1.55
Daunorubicin in acute myelocytic leukaemia. Lancet (1969) 1.54
Renal function after high dose urography in patients with renal failure. Br J Radiol (1981) 1.52
Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis. Lancet (1992) 1.52
Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA (1979) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia (2005) 1.50
Solitary plasmacytoma. I: Extramedullary soft tissue plasmacytoma. Cancer (1979) 1.50
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol (1995) 1.48
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol (1998) 1.48
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Rubidomycin in acute leukaemia in adults. Br Med J (1968) 1.45
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood (1994) 1.44
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol (2000) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
P2Y(1) purinoceptor-mediated Ca(2+) signaling and Ca(2+) wave propagation in dorsal spinal cord astrocytes. J Neurosci (2000) 1.43
Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. Q J Med (1979) 1.42
HLA-DP based resistance to Hodgkin's disease. Lancet (1989) 1.42
Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol (1994) 1.41
Incidence of Cell-Saver contamination during cardiopulmonary bypass. Ann Thorac Surg (1989) 1.41
Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol (1983) 1.40
Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia. Br J Haematol (1989) 1.40
L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J (1970) 1.39
Two blueprints for the future: cancer services in England and Wales. J R Coll Physicians Lond (2001) 1.39
Histopathology of benign non-palpable breast lesions identified by mammography. J Clin Pathol (1988) 1.39
The nephrographic pattern during excretion urography. Br Med Bull (1972) 1.36
Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol (1986) 1.34
Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr (1973) 1.33
Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet (1979) 1.31
Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol (2001) 1.28
Effect of diuresis and frequent micturition on the bacterial content of infected urine: a measure of competence of intrinsic hydrokinetic clearance mechanisms. Br J Urol (1970) 1.28
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol (1982) 1.26
The benefits of on-site cytology with ultrasound-guided fine needle aspiration in a one-stop neck lump clinic. Ann R Coll Surg Engl (2010) 1.26
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J (1978) 1.25
Excretion urography. I. Factors determining the excretion of Hypaque. Br J Radiol (1967) 1.24
Some observations on the movement of the pelvic floor and rectum with special reference to rectal prolapse. Br J Surg (1966) 1.24
Post-treatment laparotomy in the management of Hodgkin's disease. Lancet (1978) 1.23
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22
Blast crisis of chronic myeloid leukaemia (CML). II. Cell surface marker analysis of "lymphoid" and myeloid cases. Br J Haematol (1976) 1.22
Serum folic-acid and vitamin-B12 levels in anticonvulsant therapy. Br Med J (1966) 1.21
Chemotherapy of metastatic testicular tumours. Br J Urol (1980) 1.21
Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA (1981) 1.21
Renal involvement in patients with non-Hodgkin's lymphoma: clinical and pathological features in 23 cases. Hematol Oncol (1990) 1.21
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer (1979) 1.18
Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia (2007) 1.17
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature (1987) 1.16
Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2008) 1.15
High-dose excretion urography in oliguric renal failure. Lancet (1970) 1.15
Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy. Br Med J (1974) 1.15
Chemotherapy and irradiation in childhood Hodgkin's disease. Arch Dis Child (1984) 1.15
Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia (2007) 1.14
Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. Br Med J (Clin Res Ed) (1988) 1.14
Computed tomography in patients with an abdominal mass: effective and efficient? A controlled trial. Lancet (1981) 1.12